Randomized trial · people
Mazdutide: 16.65% average weight loss at 60 weeks in GLORY-2
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a placebo-controlled trial in Chinese adults with obesity, the 9 mg mazdutide arm lost an average of 16.65% of body weight over 60 weeks, and stomach side effects such as vomiting and nausea were common but mostly mild to moderate.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 461
- Published
- 2026
- Journal
- JAMA
What they tested
The team tested whether a 9 mg weekly dose of mazdutide, given with diet and exercise, lowers body weight more than placebo in Chinese adults with obesity, and how safe it is.
How the study was done
A double-blind, placebo-controlled, phase 3 randomized trial at 27 hospitals in China, in adults with a BMI (body mass index) of 30 or more, with or without type 2 diabetes. Participants got a weekly under-the-skin shot of 9 mg mazdutide or placebo (a dummy shot) for 60 weeks, alongside a lower-calorie diet and more physical activity, and 461 people who got at least 1 dose were analyzed.

Model. Individual results vary.
What they found
At week 60, body weight fell by an average of 16.65% in the mazdutide group and 1.50% in the placebo group, a between-group difference of 15.15%. A weight drop of 5% or more was reached by 84.3% of the mazdutide group versus 33.1% on placebo. Vomiting (53.1% vs 1.3%), nausea (46.9% vs 3.2%) and diarrhea (39.4% vs 6.5%) were the most common side effects, mostly mild to moderate. Side effects led 2.9% of the mazdutide group to stop treatment, versus 0% on placebo.
What it doesn’t show
The trial included only Chinese adults, with an average age of 33.9 years, and tested a single dose against placebo, not against other weight-loss drugs. It ran for 60 weeks, so it does not show what happens after that.
The paper
Gao et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026.
The compound
More studies on Mazdutide
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetesRandomized trial · people · 2026
- Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)Randomized trial · people · 2025
- Every study on Mazdutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.